Pub. Date : 2021
PMID : 34659899
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. | asciminib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 2 | Asciminib is a novel drug capable of targeting most BCR-ABL1 mutant-forms, including BCR-ABL1T315I, but remains ineffective against most BCR-ABL1T315I+ compound mutation-bearing sub-clones. | asciminib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 3 | Most importantly, we were able to show that the combinations "asciminib+ponatinib" and "asciminib+ponatinib+HU" produce synergistic apoptosis-inducing effects in CD34+/CD38- CML stem cells obtained from patients with chronic phase CML or BCR-ABL1 T315I+ CML blast phase. | asciminib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 4 | Most importantly, we were able to show that the combinations "asciminib+ponatinib" and "asciminib+ponatinib+HU" produce synergistic apoptosis-inducing effects in CD34+/CD38- CML stem cells obtained from patients with chronic phase CML or BCR-ABL1 T315I+ CML blast phase. | asciminib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |
| 5 | Together, asciminib, ponatinib and HU synergize in producing anti-leukemic effects in multi-resistant CML cells, including cells harboring T315I+ BCR-ABL1 compound mutations and CML stem cells. | asciminib | ABL proto-oncogene 1, non-receptor tyrosine kinase | Homo sapiens |